谢娜
副研究员、博导
联系方式:
xnshina@126.com
谢娜,副研究员,博士生导师。2014年于四川大学生物治疗全国重点实验室获博士学位,随后在四川大学华西医院从事博士后研究,2015-2019年赴南加州大学访问。主要从事氧化应激在肿瘤发生发展中的作用机制及干预策略研究。作为课题负责人主持国家自然科学基金面上项目、青年科学基金项目,以及四川省自然科学基金青年科学基金A类项目。以第一作者或通讯作者(含共同)在Nat Metab、Signal Transduct Target Ther、Chem Eng J、Autophagy、Small、J Control Release、J Hematol Oncol、ACS Appl Mater Interfaces、Adv Healthc Mater等国际学术期刊发表学术论文30余篇;论文总被引8800余次,H-index 38,其中10篇入选ESI高被引论文。连续2次入选全球前2%顶尖科学家年度榜单;获教育部自然科学奖一等奖(第九完成人)。
谢娜,副研究员,博士生导师。2014年于四川大学生物治疗全国重点实验室获博士学位,随后在四川大学华西医院从事博士后研究,2015-2019年赴南加州大学访问。主要从事氧化应激在肿瘤发生发展中的作用机制及干预策略研究。作为课题负责人主持国家自然科学基金面上项目、青年科学基金项目,以及四川省自然科学基金青年科学基金A类项目。以第一作者或通讯作者(含共同)在Nat Metab、Signal Transduct Target Ther、Chem Eng J、Autophagy、Small、J Control Release、J Hematol Oncol、ACS Appl Mater Interfaces、Adv Healthc Mater等国际学术期刊发表学术论文30余篇;论文总被引8800余次,H-index 38,其中10篇入选ESI高被引论文。连续2次入选全球前2%顶尖科学家年度榜单;获教育部自然科学奖一等奖(第九完成人)。
讲授《临床药理学》《科研素养与创新能力培养》《开放式医学创新讲坛》等课程;指导国家级大创项目4项,结题优秀2项;指导四川大学优秀本科毕业论文(二等奖)1篇;获四川大学本科教学成果奖校级二等奖(2024)。
研究方向:
1.氧化应激在肿瘤等疾病进展过程中的调控机制;
2.基于氧化应激的感染、肿瘤等疾病进展监测及干预策略。
代表性论文:
1. Zhang Y, Huang Y, Liu S, Tian H, Chang Q, Zhang T, Yan F, Ye Q, Huang C, Xie N. Copper-Ddriven nanoadjuvant Rreverses Iimmunosuppression in Ccolorectal cancer by Oorchestrating Mmetabolic Ddysfunction and Iinnate immune activation. Chem Eng J. 2026.540:177486
2. Chang Q, Cheng W, Tian H, Qin S, Zhang Y, Zuo J, Pu W, Lu S, Xie N. Zinc‐Coordination‐Driven Pyroptosis Nano‐Inductor Sensitizes Colorectal Cancer Chemo‐Immunotherapy by Specific Delivery and Cell Stemness Suppression. MedComm-Oncology. 5 (2), e70075
3. Feng S*, Xie N*, Liu Y, Qin C, Savas AC, Wang TY, Li S, Rao Y, Shambayate A, Chou TF, Brenner C, Huang C, Feng P. Cryptic phosphoribosylase activity of NAMPT restricts the virion incorporation of viral proteins. Nat Metab. 2024;6(12):2300-18.
4. Zhang X, Tian H, Chen Y, Liang B, Nice EC, Huang C, Xie N#, Zheng S#. A metal-organic nanoframework for efficient colorectal cancer immunotherapy by the cGAS-STING pathway activation and immune checkpoint blockade. J Nanobiotechnology. 2024;22(1):592.
5. Shen G*, Liu J*, Yang H, Xie N#, Yang Y#. mRNA therapies: Pioneering a new era in rare genetic disease treatment. J Control Release. 2024;369:696-721.
6. Huang Y*, Guo X*, Wu Y*, Chen X, Feng L, Xie N#, Shen G#. Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment. Signal Transduct Target Ther. 2024; 9(1):34. (ESI高被引论文)
7. Deng K, Tian H, Zhang T, Gao Y, Nice EC, Huang C, Xie N#, Ye G#, Zhou Y#. Chemo-photothermal nanoplatform with diselenide as the key for ferroptosis in colorectal cancer. J Control Release. 2024;366:684-693. (ESI高被引论文)
8. Xie N, Shen G, Gao W, Huang Z, Huang C#, Fu L#. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023;8(1):9. (ESI高被引论文)
9. Lu S, Tian H, Li L, Li B, Yang M, Zhou L, Jiang H, Li Q, Wang W, Nice EC, Xie N#, Huang C#, Liu L#. Nanoengineering a Zeolitic Imidazolate Framework-8 Capable of Manipulating Energy Metabolism against Cancer Chemo-Phototherapy Resistance. Small. 2022: e2204926
10. An Y*, Jiang J*, Zhou L*, Shi J, Jin P, Li L, Peng L, He S, Zhang W, Huang C, Zou B#, Xie N#. Peroxiredoxin 1 is essential for natamycin-triggered apoptosis and protective autophagy in hepatocellular carcinoma. Cancer Lett. 2021; 521:210-223.
11. Huang Z*, Xie N*, Illes P, Di Virgilio F, Ulrich H, Semyanov A, Verkhratsky A, Sperlagh B, Yu SG, Huang C, Tang Y. From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther. 2021;6(1):162 (ESI高被引论文)
12. Wu P*, Gao W*, Su M, Nice EC, Zhang W, Lin J#, Xie N#. Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. Front Cell Dev Biol. 2021; 9: 357.(ESI高被引论文)
13. Xie N*, Zhang L*, Gao W*, Huang C, Huber PE, Zhou X, Li C#, Shen G#, Zou B#. NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct Target Ther. 2020;5(1):227. (ESI高被引论文)
14. Zhang Z*, Zhou L*, Xie N*, Nice EC, Zhang T, Cui Y, Huang C. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther. 2020;5(1):113.(ESI高被引论文)
15. Xie N*, Yuan K*, Zhou L, Wang K, Chen HN, Lei Y, Lan J, Pu Q, Gao W, Zhang L, Shen G, Li Q, Xiao H, Tang H, Xiang R, He M, Feng P, Nice EC, Wei Y, Zhang H, Yang J, Huang C. PRKAA/AMPK restricts HBV replication through promotion of autophagic degradation. Autophagy. 2016; 12(9): 1507-20.

